Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Raven and BTI collaborate in cancer stem cell discovery
Under the terms of the agreement, Raven will license its proprietary whole cell immunization technology for use with Bioprocessing Technology Institute (BTI)’s stem cells. Raven will screen the
Under the terms of the agreement, Raven will license its proprietary whole cell immunization technology for use with Bioprocessing Technology Institute (BTI)’s stem cells. Raven will screen the
Under this agreement, Sangamo will provide a non-exclusive, worldwide license to Open Monoclonal Technologies (OMT) for the commercial use of transgenic animals generated using Sangamo’s proprietary zinc finger
The offer represents an 18% premium over the closing price of LifeCell’s stock on April 4, 2008, and a 26% premium over the 90-day volume weighted average trading
The company expects that the net proceeds of the offering will be approximately $13.4 million after deducting underwriting discounts and other expenses associated with the offering. The company
The new center, which will be located in Camp Hill, is said to have been designed with patient comfort and efficiency in mind, and will have a total
The $30 million in funding will be provided by Deerfield from two sources: $20 million under a royalty and funding agreement and $10 million from the sale of
Paul Viviano, chairman of the board and CEO of Alliance Imaging, said: “This acquisition and the opportunity to develop a strategic relationship with Accuray provides Alliance’s national team
In the second quarter of 2008, the company intends to initiate the randomized, double-blind, placebo controlled Phase III program to evaluate the efficacy and safety of Ketotransdel in
Ceragenix may earn certain non-sales based milestone payments of up to $3.5 million upon the accomplishment of three specified events inclusive of certain product launch specific considerations. The
In exchange for these rights, which include a license to intellectual property (IP) that Targeted Genetics may find necessary to develop and commercialize an Huntington’s disease (HD) product,